Liposomal sunitinib for ocular drug delivery: A potential treatment for choroidal neovascularization

MLA

Shirin Tavakoli, et al. “Liposomal Sunitinib for Ocular Drug Delivery: A Potential Treatment for Choroidal Neovascularization.” International Journal of Pharmaceutics, vol. 620, May 2022, p. 121725. EBSCOhost, https://doi.org/10.1016/j.ijpharm.2022.121725.

APA

Shirin Tavakoli, Jooseppi Puranen, Sina Bahrpeyma, Veera E. Lautala, Suvi Karumo, Tatu Lajunen, Eva M. del Amo, Marika Ruponen, & Arto Urtti. (2022). Liposomal sunitinib for ocular drug delivery: A potential treatment for choroidal neovascularization. International Journal of Pharmaceutics, 620, 121725. https://doi.org/10.1016/j.ijpharm.2022.121725

Chicago

Shirin Tavakoli, Jooseppi Puranen, Sina Bahrpeyma, Veera E. Lautala, Suvi Karumo, Tatu Lajunen, Eva M. del Amo, Marika Ruponen, and Arto Urtti. 2022. “Liposomal Sunitinib for Ocular Drug Delivery: A Potential Treatment for Choroidal Neovascularization.” International Journal of Pharmaceutics 620 (May): 121725. doi:10.1016/j.ijpharm.2022.121725.